

Venus bags additional US patent for Vancoplus

29 May 2014 | Regulatory | By BioSpectrum Bureau



Singapore: India's Chandigarh based Venus Remedies has bagged an additional patent for Vancoplus from USPTO. Vancoplus is an antibiotic adjuvant entity, effective against the deadly resistance of Methicillin Resistant Staphylococcus Aureus (MRSA). Developed by Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than 9 percent success rate.

Quoting on the patent, Dr Manu Chaudhary, joint managing director, Venus Remedies said, "The patent is valid till 2032. We have already initiated the process for pre-IND meeting with USFDA, and we are quite optimistic about getting a fast track approval for this product as MRSA is under the list of limited pathogens, identified under GAIN act by FDA, and Vancoplus falls in the QIDP category."

Venus Remedies already has a product patent for Vancoplus from USPTO, this additional patent with broader coverage for use and method of treatment will be beneficial for the company. The formulation will be commercialized in the US market through technology transfer or outlicensing of exclusive marketing rights route.

Vancoplus is a novel antibiotic adjuvant entity, highly effective against MRSA, VISA, hGISA and mixed bacterial infections of gram negative and gram positive pathogens. It is the best and safest option to address such infections. It is also active against different mechanisms of resistance such as Cell Membrane impermeability, Efflux pumps, Biofilms, which no other therapeutic options available, are able to address.

It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product, which has received an overwhelming response from the medical fraternity in India, since its launch in the country four years ago and is growing with more than 25 percent CAGR in the Indian market.

In USA alone, MRSA is associated with a staggering 90,000 infections and an estimated 19,000 deaths annually. Global Antibacterial Market is slated to reach approx. \$64 bn by the year 2018, with a growth rate of 7.5 percent. Vancoplus is segmented in the Hospital Treated Infection Market which is growing at a rate of 2.7 percent by taking the sales of competitor brands in 2013 as addressable market for Vancoplus, which stands at \$261 million.

"In view of the steep rise in the prevalence of MRSA, VRSA and hGISA infections, Vancoplus will be the need of the hour, due to its high potency against these infections and mixed bacterial infection of gram negative and gram positive pathogens. We have developed Vancoplus to address this unmet need," said Dr Manu Chaudhary, Joint Managing Director, Venus Remedies Ltd, and Director, Research, VMRC.

Besides this, Venus has also secured US patent for its novel research products ELORES, Potentox and Achnil.